Long-term Extension Study of Safety During Treatment With Tocilizumab (MRA) in Patients Completing Treatment in MRA Core Studies
Phase of Trial: Phase III
Latest Information Update: 01 Dec 2016
At a glance
- Drugs Tocilizumab (Primary) ; Antirheumatics
- Indications Rheumatoid arthritis
- Focus Adverse reactions; Therapeutic Use
- Sponsors Roche
- 01 Dec 2016 Results (n=134) of the 5-year LTE study of AMBITION study, published in The Journal of Rheumatology
- 29 Sep 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 29 Sep 2014 Planned End Date changed from 1 Aug 2013 to 1 Apr 2013 as reported by ClinicalTrials.gov.